C7C1 for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 500+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 220+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 25 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
C7C1 may be beneficial for
COVID-19 according to the study below.
COVID-19 involves the interplay of 500+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 11,000+ potential treatments.
c19early.org analyzes
220+ treatments.
We have not reviewed C7C1 in detail.
, Anti-SARS-CoV-2 VHH and C7C peptide fused with Angiopep-2 efficiently traverse blood-brain barrier model and neutralizes virus, Frontiers in Microbiology, doi:10.3389/fmicb.2026.1827887
Introduction The therapy for SARS-CoV-2-related CNS infection relies on treating neuroinflammation and associated damage, rather than a specific antiviral. The lack of specific antiviral therapeutics is mainly attributed to the limited permeability of drugs across the blood-brain barrier. Methods In this paper, we present a detailed pipeline for selecting VHHs (single variable domain of llama heavy chain antibody) and 7-mer cyclic peptides (C7C) from phage-display libraries that bind to the spike protein and SARS-CoV-2 virion. Soluble VHH and C7C peptides overexpressed in the E. coli SHuffle Express, which enables the formation of the disulfide bond essential for proper VHH and C7C folding and function, were purified and rigorously tested for their capacity to neutralize pseudovirus, cell toxicity, hemocompatibility, etc. The best VHH and C7C candidates with favorable attributes were then fused with the CNS-homing peptide Angiopep-2 and thoroughly assessed for the ability to neutralize the virus along with other safety attributes mentioned earlier. Results and discussion The best VHH and C7C candidates, VHH E12 and C7C 18 , tested for their ability to neutralize live virus in a plaque reduction neutralization test, showed EC 50 0.045 μg/mL and 0.01 μg/mL, respectively. Both VHH E12 and C7C 18 , however, fail to cross the blood-brain barrier in vitro, thus were fused with CNS-homing peptide Angiopep-2. VHH E12 -Angiopep-2 and C7C 18 -Angiopep-2 fusion constructs showed increased crossing across the blood-brain barrier by 5.4-fold and 11.2-fold, respectively, while maintaining their ability to neutralize the virus. Molecules generated here, particularly C7C 18 -Angiopep-2, hold merit for further in vivo testing and preclinical studies.